Specification Amendments:

In the specification, at page 1, lines 5-6, please amend the paragraph as follows:

~~--This application is a continuation of USSN 09/557,092, which claims priority from USSN 60/130,847, filed April 22, 1999 and 60/137,214, filed June 1, 1999.~~ This application is a continuation of pending U.S. Patent Application Serial No. 10/061,658, filed February 1, 2002, which is a continuation of U.S. Patent Application Serial No. 09/557,092, filed April 21, 2000, now abandoned, which was a continuation in part of U.S. Patent Application Serial No. 60/130,847, filed April 22, 1999, now abandoned, and U.S. Patent Application Serial No. 60/137,214, filed June 1, 1999, now abandoned. The instant application claims priority from each of these earlier-filed applications.—

In the specification, at page 4, line 2, please add the following new sentence after the word "experiments."

--The hybridoma that produces the α1-I domain antibody AJH10 was deposited under the Budapest Treaty on August 2, 2001 with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 (ATCC PTA-3580). Other materials necessary to make AJH10 are available in the public domain to those of ordinary skill in the art.--

In the specification, at page 4, please amend the description of Figure 4 at lines 11-12 as follows:

--Figure 4. Location of the Epitope for the anti- α1-I domain Blocking mAbs. A. Figure 4.A illustrates the amino ~~Amino~~ acid sequence of the rat (top) (SEQ ID NO: 5) and human (below) (SEQ ID NO: 6) ~~α1-I domain~~ α1-I integrin polypeptide sequences. --

In the specification, at page 4, lines 19-20, please amend the description of Figure 5 as follows:

~~--Figure 5. Amino acid sequence of the human α1β1 integrin polypeptide sequence (SEQ ID NO: 9). The amino acid sequence of the α1-I domain (SEQ ID NO: 10 is shown in the~~

~~box.~~ Figure 5. Figure 5 illustrates the amino acid sequence of the human α1-I integrin polypeptide sequence (SEQ ID NO: 9). The amino acid sequence of the epitope for the anti-α1-I domain blocking mAbs (SEQ ID NO: 8) is shown in the box.--

In the specification, at page 25, lines 13-14, please amend the sentence as follows.
--It is concluded that integrins α1β1 and ~~α1β1~~ α2β1 play important roles in BL-induced pulmonary fibrosis and use of antiα1β1 or antiα2β1antibody has great antifibrotic potential *in vivo*.--

In the specification, at page 31, lines 6-8, please amend the sentence as follows.
--The clarified supernatant from cells lysed in PBS was loaded onto a gluthione Sepharose™ 4B column (Pharmacia) which was washed extensively with PBS.--

In the specification, at page 31, lines 12-13, please amend the sentence as follows.
--The flow-through and wash fractions were pooled and loaded onto a Q Sepharose™ FF column (Pharmacia).--

In the specification, at page 31, lines 14-17, please amend the sentence as follows.
--The purified I domain displayed its predicted mass (Lee et al. (1995) *Structure* 3, 1333-1340, 871 Da) by electrospray ionization mass spectrometry (ESI-MS), migrated as single band by SDS-PAGE, and the protein eluted as a single peak of appropriate size by size exclusion chromatography on a Superose ™ FPLC column (Pharmacia).--

In the specification, at page 32, lines 17-23, please amend the paragraph as follows.
--The human and rat sequences differ by only 12 amino acids, 4 of which lie in a stretch of 6 amino acids (aa ~~92~~ 91-~~97~~ 96, Fig. 4A) (SEQ ID NOs: 8 and 7, respectively) adjacent to the critical ~~threonine~~ glutamine (Fig. 4A, aa ~~98~~ 97) within the MIDAS motif. To test the hypothesis that the 6 amino acid residues, Val-Gln-Arg-Gly-Gly-Arg, comprise the

eptitope for the blocking mAbs, we constructed a chimeric I domain (RΔH), ~~exchanging~~ which exchanged the rat residues G ~~92~~ 91, R ~~93~~ 92 Q ~~94~~ 93, and L ~~97~~ 96 for the corresponding human residues, V, Q, R, and R, respectively.--